Listed

Sagimet Biosciences Inc.

SGMTNasdaqCIK 1400118HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2023
Operating income−$15.8m, Q2 FY2026
Net income−$14.0m, Q2 FY2026
Sagimet Biosciences Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m2.0Revenue, Q3 FY2023, three months to 2023-09-30$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-12, accession 0001558370-25-002747. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m5.0Research and development, Q3 FY2023, three months to 2023-09-30$5.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure5.7Research and development, Q4 FY2023, three months to 2023-12-31$5.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-12, accession 0001558370-25-002747. Derived: 12-month figure less the 9-month figure.Report this figure5.3Research and development, Q1 FY2024, three months to 2024-03-31$5.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure6.3Research and development, Q2 FY2024, three months to 2024-06-30$6.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure12.7Research and development, Q3 FY2024, three months to 2024-09-30$12.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure14.2Research and development, Q4 FY2024, three months to 2024-12-31$14.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure15.3Research and development, Q1 FY2025, three months to 2025-03-31$15.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure7.2Research and development, Q2 FY2025, three months to 2025-06-30$7.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure9.7Research and development, Q3 FY2025, three months to 2025-09-30$9.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure6.7Research and development, Q4 FY2025, three months to 2025-12-31$6.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure7.0Research and development, Q1 FY2026, three months to 2026-03-31$7.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure11.5Research and development, Q2 FY2026, three months to 2026-06-30$11.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Operating income$m(7.5)Operating income, Q3 FY2023, three months to 2023-09-30−$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure(9.5)Operating income, Q4 FY2023, three months to 2023-12-31−$9.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-12, accession 0001558370-25-002747. Derived: 12-month figure less the 9-month figure.Report this figure(8.8)Operating income, Q1 FY2024, three months to 2024-03-31−$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure(10.6)Operating income, Q2 FY2024, three months to 2024-06-30−$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure(16.9)Operating income, Q3 FY2024, three months to 2024-09-30−$16.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure(18.2)Operating income, Q4 FY2024, three months to 2024-12-31−$18.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure(19.9)Operating income, Q1 FY2025, three months to 2025-03-31−$19.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(11.9)Operating income, Q2 FY2025, three months to 2025-06-30−$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure(14.3)Operating income, Q3 FY2025, three months to 2025-09-30−$14.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure(10.8)Operating income, Q4 FY2025, three months to 2025-12-31−$10.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure(11.7)Operating income, Q1 FY2026, three months to 2026-03-31−$11.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(15.8)Operating income, Q2 FY2026, three months to 2026-06-30−$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Net income$m(6.4)Net income, Q3 FY2023, three months to 2023-09-30−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure(8.2)Net income, Q4 FY2023, three months to 2023-12-31−$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-12, accession 0001558370-25-002747. Derived: 12-month figure less the 9-month figure.Report this figure(6.6)Net income, Q1 FY2024, three months to 2024-03-31−$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure(8.1)Net income, Q2 FY2024, three months to 2024-06-30−$8.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure(14.6)Net income, Q3 FY2024, three months to 2024-09-30−$14.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure(16.2)Net income, Q4 FY2024, three months to 2024-12-31−$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure(18.2)Net income, Q1 FY2025, three months to 2025-03-31−$18.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure(10.4)Net income, Q2 FY2025, three months to 2025-06-30−$10.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure(12.9)Net income, Q3 FY2025, three months to 2025-09-30−$12.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure(9.6)Net income, Q4 FY2025, three months to 2025-12-31−$9.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure(10.7)Net income, Q1 FY2026, three months to 2026-03-31−$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure(14.0)Net income, Q2 FY2026, three months to 2026-06-30−$14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Diluted EPS$ per share(0.35)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figurenot reported(0.23)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure(0.25)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure(0.45)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figurenot reported(0.56)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(0.32)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure(0.40)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figurenot reported(0.33)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(0.26)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Basic EPS$ per share(0.35)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figurenot reported(0.23)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure(0.25)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure(0.45)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figurenot reported(0.56)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(0.32)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure(0.40)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figurenot reported(0.33)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(0.26)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure

Balance sheet

Cash and equivalents$165.9m, Q2 FY2026
Shareholders' equity$256.2m, Q2 FY2026
Sagimet Biosciences Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m102Cash and equivalents, Q3 FY2023, at 2023-09-30$101.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001558370-23-018700.Report this figure75.1Cash and equivalents, FY2023, at 2023-12-31$75.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure177Cash and equivalents, Q1 FY2024, at 2024-03-31$176.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-15, accession 0001558370-24-008205.Report this figure96.0Cash and equivalents, Q2 FY2024, at 2024-06-30$96.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001558370-24-012136.Report this figure77.0Cash and equivalents, Q3 FY2024, at 2024-09-30$77.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure75.8Cash and equivalents, FY2024, at 2024-12-31$75.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figure64.7Cash and equivalents, Q1 FY2025, at 2025-03-31$64.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure42.3Cash and equivalents, Q2 FY2025, at 2025-06-30$42.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure32.5Cash and equivalents, Q3 FY2025, at 2025-09-30$32.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure35.0Cash and equivalents, FY2025, at 2025-12-31$35.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure36.6Cash and equivalents, Q1 FY2026, at 2026-03-31$36.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure166Cash and equivalents, Q2 FY2026, at 2026-06-30$165.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Current assets$m103Current assets, Q3 FY2023, at 2023-09-30$102.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001558370-23-018700.Report this figure96.6Current assets, FY2023, at 2023-12-31$96.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure194Current assets, Q1 FY2024, at 2024-03-31$194.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001558370-24-008205.Report this figure167Current assets, Q2 FY2024, at 2024-06-30$166.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001558370-24-012136.Report this figure157Current assets, Q3 FY2024, at 2024-09-30$157.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure153Current assets, FY2024, at 2024-12-31$152.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figure146Current assets, Q1 FY2025, at 2025-03-31$146.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure127Current assets, Q2 FY2025, at 2025-06-30$127.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure119Current assets, Q3 FY2025, at 2025-09-30$119.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure116Current assets, FY2025, at 2025-12-31$116.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure108Current assets, Q1 FY2026, at 2026-03-31$107.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure244Current assets, Q2 FY2026, at 2026-06-30$244.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Total assets$m103Total assets, Q3 FY2023, at 2023-09-30$102.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001558370-23-018700.Report this figure96.7Total assets, FY2023, at 2023-12-31$96.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figure195Total assets, Q1 FY2024, at 2024-03-31$194.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001558370-24-008205.Report this figure189Total assets, Q2 FY2024, at 2024-06-30$189.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001558370-24-012136.Report this figure175Total assets, Q3 FY2024, at 2024-09-30$174.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure160Total assets, FY2024, at 2024-12-31$160.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figure146Total assets, Q1 FY2025, at 2025-03-31$146.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure137Total assets, Q2 FY2025, at 2025-06-30$137.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure128Total assets, Q3 FY2025, at 2025-09-30$128.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure116Total assets, FY2025, at 2025-12-31$116.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure108Total assets, Q1 FY2026, at 2026-03-31$107.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure263Total assets, Q2 FY2026, at 2026-06-30$263.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Current liabilities$m5.0Current liabilities, Q3 FY2023, at 2023-09-30$5.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001558370-23-018700.Report this figure5.7Current liabilities, FY2023, at 2023-12-31$5.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-12, accession 0001558370-25-002747.Report this figurenot reportednot reportednot reported4.5Current liabilities, FY2024, at 2024-12-31$4.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figurenot reported7.2Current liabilities, Q2 FY2025, at 2025-06-30$7.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure9.1Current liabilities, Q3 FY2025, at 2025-09-30$9.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure5.1Current liabilities, FY2025, at 2025-12-31$5.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure5.3Current liabilities, Q1 FY2026, at 2026-03-31$5.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure5.4Current liabilities, Q2 FY2026, at 2026-06-30$5.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Total liabilities$m5.1Total liabilities, Q3 FY2023, at 2023-09-30$5.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001558370-23-018700.Report this figure5.7Total liabilities, FY2023, at 2023-12-31$5.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure4.5Total liabilities, Q1 FY2024, at 2024-03-31$4.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001558370-24-008205.Report this figure5.7Total liabilities, Q2 FY2024, at 2024-06-30$5.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001558370-24-012136.Report this figure4.1Total liabilities, Q3 FY2024, at 2024-09-30$4.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure4.5Total liabilities, FY2024, at 2024-12-31$4.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure7.2Total liabilities, Q1 FY2025, at 2025-03-31$7.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figurenot reportednot reported5.1Total liabilities, FY2025, at 2025-12-31$5.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figurenot reported7.3Total liabilities, Q2 FY2026, at 2026-06-30$7.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure
Shareholders' equity$m97.9Shareholders' equity, Q3 FY2023, at 2023-09-30$97.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure91.1Shareholders' equity, FY2023, at 2023-12-31$91.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-11, accession 0001104659-26-026140.Report this figure190Shareholders' equity, Q1 FY2024, at 2024-03-31$190.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure183Shareholders' equity, Q2 FY2024, at 2024-06-30$183.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure171Shareholders' equity, Q3 FY2024, at 2024-09-30$170.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure156Shareholders' equity, FY2024, at 2024-12-31$155.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure139Shareholders' equity, Q1 FY2025, at 2025-03-31$139.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure130Shareholders' equity, Q2 FY2025, at 2025-06-30$130.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure119Shareholders' equity, Q3 FY2025, at 2025-09-30$119.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure111Shareholders' equity, FY2025, at 2025-12-31$111.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure102Shareholders' equity, Q1 FY2026, at 2026-03-31$102.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure256Shareholders' equity, Q2 FY2026, at 2026-06-30$256.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure

Cash flow

Operating cash flow−$11.1m, Q2 FY2026
Sagimet Biosciences Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(3.9)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001558370-24-015623. Derived: 9-month figure less the 6-month figure.Report this figure(7.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$7.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-12, accession 0001558370-25-002747. Derived: 12-month figure less the 9-month figure.Report this figure(6.2)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure(5.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011301. Derived: 6-month figure less the 3-month figure.Report this figure(19.6)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$19.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110846. Derived: 9-month figure less the 6-month figure.Report this figure(11.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure(14.5)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$14.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(9.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-343441. Derived: 6-month figure less the 3-month figure.Report this figure(10.2)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$10.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110846. Derived: 9-month figure less the 6-month figure.Report this figure(11.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-11, accession 0001104659-26-026140. Derived: 12-month figure less the 9-month figure.Report this figure(8.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure(11.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-343441. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)53.11m, Q2 FY2026
Sagimet Biosciences Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30period not labelled2023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.2Diluted shares (weighted), period not labelled, three months to 2022-09-30185,084 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001558370-23-018700.Report this figure0.2Diluted shares (weighted), period not labelled, three months to 2023-03-31185,137 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0001558370-24-008205.Report this figure0.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30189,520 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001558370-24-012136.Report this figure18.2Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3018,194,682 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure29.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3129,039,427 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001558370-25-006836.Report this figure31.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3031,913,887 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001558370-25-011301.Report this figure32.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3032,143,336 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure32.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3132,195,345 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure32.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3032,195,366 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure32.5Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3032,464,893 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110846.Report this figure32.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3132,559,704 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001104659-26-059006.Report this figure53.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3053,114,533 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343441.Report this figure

Shares outstanding: 30.67mShares outstanding, period not labelled, at 2024-11-0830,674,855 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2024-11-14, accession 0001558370-24-015623.Report this figure at Nov 8, 2024, from the cover of the 10-Q filed Nov 14, 2024.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.